The cardiorenal anemia syndrome in congestive heart failure (CHF) is an independent risk factor for vascular morbidity and mortality. Several factors play a role in the pathogenesis of anemia in CHF, including inflammation, impaired renal function, use of certain antihypertensive or cardioprotective agents, and gastrointestinal or urinary losses of essential hemopoietic factors. Several trials evaluated the effects of administering erythropoietin (EPO) and/or iron to patients with CHF. Even though most of them were uncontrolled studies, their results suggest that EPO treatment might be beneficial in CHF. Nevertheless, more studies are needed and certain issues should be resolved, particularly the optimal hemoglobin level, before EPO can become part of the treatment of patients with CHF.
AnandI.S., ChandrashekharY., FerrariR.Pathogenesis of edema in chronic anemia: studies of body water and sodium, renal function, haemodynamics and plasma hormones.Br Heart J.1993; 70: 357–362.
2.
SilverbergD.S., WexlerD., IainaA.The importance of anemia and its correction in the management of severe congestive heart failure.Eur J Heart Fail.2002; 4: 681–686.
3.
SabatineM.S., MorrowD.A., GiuglianoR.P.Association of hemoglobin levels with clinical outcomes in acute coronary syndromes.Circulation.2005; 111: 2042–2049.
4.
McCulloughP.A., LeporN.E.The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment.Rev Cardiovasc Med.2005; 6: 1–10.
5.
SilverbergD.S., WexlerD., BlumM.The interaction between heart failure, renal failure and anemia: the cardio–renal anemia syndrome.Blood Purif.2004; 22: 277–284.
6.
SilverbergD.S., WexlerD., IainaA.The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?J Nephrol.2004; 17: 749–761.
7.
SilverbergD.S., WexlerD., BlumM.The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations.J Am Coll Cardiol.2000; 35: 1737–1744.
8.
WexlerD., SilverbergD.S., ShepsD.Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure.Int J Cardiol.2004; 96: 79–87.
9.
SilverbergD.S., WexlerD., IainaA., SteinbruchS., WollmanY., SchwartzD.Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.Int Urol Nephrol.2006; 38: 295–310.
10.
TangW.H., MillerH., PartinM., HarrisC.M., YoungJ.B.Anemia in ambulatory patients with chronic heart failure: a single-center clinical experience derived from electronic medical records.J Am Coll Cardiol.2003; 41(suppl l): S1061–S1075.
11.
IversonP.O., WolbaekP.R., TonnessenT., ChristensenG.Decreased hematopoiesis in bone marrow of mice with congestive heart failure.Am J Physiol.2002; 282: R166–R172.
12.
Torre-AmioneG., BozkurtB., DeswalA.An overview of tumor necrosis factor and the failing human heart.Curr Opin Cardiol.1999; 14: 206–210.
13.
MeansR.T.Advances in the anemia of chronic disease.Int J Hematol.1999; 70: 7–12.
14.
VolpeM., TrittoC., TestaU.Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic and hormonal profiles.Am J Cardiol.1994; 74: 468–473.
15.
DeicherR., HorlW.H.Hepcidin: a molecular link between inflammation and anaemia.Nephrol Dial Transplant.2004; 19: 521–524.
16.
DetivaudL., NemethE., BoudjemaK.Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function.Blood.2005; 10: 746–748.
17.
LaskarS.R., DriesD.L.The prognostic significance of renal dysfunction in patients with chronic systolic heart failure.Curr Cardiol Rep.2003; 5: 205–210.
18.
FineL.G., BandyopadhayD., NormanJ.T.Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia.Kidney Int Suppl.2000; 75: S22–S26.
19.
VaziriN.D.Erythropoietin and transferrin metabolism in nephritic syndrome.Am J Kidney Dis.2001; 38: 1–8.
20.
MacdougallI.C.The role of ACE inhibitors and angiotensin II receptor blockers in the response to erythropoietin.Nephrol Dial Transplant.1999; 14: 1836–1841.
21.
MarathiasK.P., AgroyannisB., MavromoustakosT., MatsoukasJ., VlahakosD.V.Hct-lowering effect following inactivation of renin–angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.Curr Top Med Chem.2004; 4: 483–486.
22.
IshaniA., WeinhandlE., ZhaoZ.Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia and the impact of incident anemia on mortality in patients with left ventricular dysfunction.J Am Coll Cardiol.2005; 45: 391–399.
23.
BroxA.G., MangelJ., HanleyJ.A., St LouisG., MongrainS., GagnonR.F.Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins.Transplantation.1998; 66: 1053–1058.
24.
YanaseT., MakiT., NawataH., KatoK., IbayashiH.Effect of angiotensin II on secretion of adrenal androgens.Endocrinol Jpn.1984; 31: 741–747.
25.
AziziM., RousseauA., EzanE.Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.;Clin Invest.1996; 97: 839–844.
26.
KrackA., SharmaR., FigullaH.R., AnkerS.D.The importance of the gastrointestinal system in the pathogenesis of heart failure.Eur Heart J.2005; 26: 2368–2374.
27.
WitteK.K., ClarkA.L.Nutritional abnormalities contributing to cachexia in chronic illness.Int J Cardiol.2002; 85: 23–31.
28.
NanasJ.N., MatsoukaC., KarageorgopoulosD.Etiology of anemia in patients with advanced heart failure.J Am Coll Cardiol.2006; 48: 2485–2489.
29.
AnandI., McMurrayJ.J., WhitmoreJ.Anemia and its relationship to clinical outcome in heart failure.Circulation.2004; 110: 149–154.
30.
HorwichT.B., FonarowG.C., HamiltonM.A., MacLellanW.R., BorensteinJ.Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.J Am Coll Cardiol.2002; 39: 1780–1786.
31.
SzachniewiczJ., Petruk-KowalczykJ., MajdaJ.Anaemia is an independent predictor of poor outcome in patients with chronic heart failure.Int J Cardiol.2003; 90: 303–308.
32.
MozaffarianD., NyeR., LevyW.C.Anemia predicts mortality in severe heart failure.J Am Coll Cardiol.2003; 41: 1933–1939.
33.
SharmaR., FrancisD.P., PittB., Poole-WilsonP.A., CoatsA.J.S., AnkerS.D.Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial.Eur Heart J.2004; 25: 1021–1028.
34.
McClellanW.M., FlandersW.D., LangstonR.D., JurkovitzC., PresleyR.Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study.J Am Soc Nephrol.2002; 13: 1928–1936.
35.
EzekowitzJ.A., McAlisterF.A., ArmstrongP.W.Anemia is common in heart failure and is associated with poor outcomes.Circulation.2003; 107: 223–225.
36.
SarnakM.J., TighiouartH., ManjunathG.Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study.J Am Coll Cardiol.2002; 40: 27–33.
37.
GoA.S., YangJ., AckersonL.M.Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure.Circulation.2006; 113: 2713–2723.
38.
NordykeR.J., KimJ.J., GoldbergG.A.Impact of anemia on hospitalization time, charges and mortality in patients with heart failure.Value Health.2004; 7: 464–471.
39.
SilvaR.P., BarbosaP.H., KimuraO.S.Prevalance of anemia and its association with cardio-renal syndrome.Int J Cardiol.2007; 120: 232–236.
40.
LevinA., ThompsonC.R., EthierJ.Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.Am J Kidney Dis.1999; 34: 125–134.
41.
AessoposA., DeftereosS., FarmakisD.Cardiovascular adaptation to chronic anemia in the elderly. Echocardiographic study.Clin Invest Med.2004; 27: 265–273.
42.
SchunkertH., HenseH.W.A heart price to pay for anemia.Nephrol Dial Transplant.2001; 16: 445–448.
43.
WeissG., GoodnoughL.T.Anemia of chronic disease.N Engl J Med.2005; 352: 1011–1023.
44.
LiuX., XieW, LiuP.Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia—reperfusion.Life Sci.2006; 78: 2255–2264.
45.
KoureaK., ParissisJ.T., FarmakisD.Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure.Atherosclerosis. In press.
46.
NamiuchiS., KagayaY., OhtaJ.High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention.J Am Coll Cardiol.2005; 45: 1406–1412.
47.
ParsaC.J., MatsumotoA., KimJ.A novel protective effect of erythropoietin in the infarcted heart.J Clin Invest.2003; 112: 999–1007.
48.
HeeschenC., AicherA., LehmannR.Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.Blood.2003; 102: 1340–1346.
49.
PalazzuoliA., SilverbergD., IovineF.Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.Am Heart J.2006; 152(1096): e9–e15.
50.
PalazzuolliA., SilverbergD., IovineF.Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.Am Heart J.2007; 154(645): e9–e15.
51.
MishraT.K., MishraS.K., MohantyN.K., RathP.K.Prevalence, prognostic importance and therapeutic implications of anemia in heart failure.Indian Heart J.2005; 57: 670-, 2005.
52.
ManciniD.M., KatzS.D., LangC.C., LaMancaJ., HudaihedA., AndroneA-S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.Circulation.2003; 107: 294–299.
53.
SilverbergD.S., WexlerD., ShepsD.The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.J Am Coll Cardiol.2001; 37: 1775–1780.
54.
SilverbergD.S., WexlerD., BlumM.The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.Nephrol Dial Transplant.2003; 18: 141–146.
55.
SilverbergD.S., WexlerD., BlumM.Effects of treatment with epoetin Beta on outcomes in patients with anaemia and chronic heart failure.Kidney Blood Press Res.2005; 28: 41–47.
56.
EgrieJ.C., DwyerE., BrowneJ.K., HitzA., LykosM.A.Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.Exp Hematol.2003; 31: 290–299.
57.
Van VeldhuisenD.J., DicksteinK., Cohen-SolalA.Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing-regimens of darbepoetin-alfa on hemoglobin response and symptoms in patients with heart failure and anemia [abstract].J Am Coll Cardiol.2006; 47(suppl l): 61A.
58.
Van VeldhuisenD.J., DicksteinK., Cohen-SolalA.Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin-alfa in patients with heart failure and anemia.Eur Heart J.2007; 28: 2208–2216.
59.
ClelandJ.G.F., SullivanJ.T., BallS.Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia. A pharmacokinetic and pharmacodynamic investigation.J Cardiovasc Pharmacol.2005; 46: 155–161.
60.
PonikowskiP., AnkerS.D., SzachniewiczJ.Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure.J Am Coll Cardiol.2007; 49: 753–762.
61.
Van VeldhuisenD.J., McMurrayJ.V.Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial.Eur J Heart Fail.2007; 9: 110–112.
62.
ToblliJ.E., LombranaA., DuarteP., GennaroF.D.Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.J Am Coll Cardiol.2007; 50: 1657–1665.
63.
Bolgerá.P., BartlettF.R., PenstonH.S.Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.J Am Coll Cardiol.2006; 48: 1225–1227.
64.
SinghA.K., SzczechL., TangK.L.Correction of anemia with epoetin alfa in chronic kidney disease.N Engl J Med.2006; 355: 2085–2098.
65.
DrüekeT.B., LocatelliF., ClyneN.Normalization of haemoglobin level in patients with chronic kidney disease and anemia.N Engl J Med.2006; 355: 2071–2084.
66.
YoungJ.B., AnandI.S., DiazR.Reduction of Events With Darbepoetin Alfa in Heart Failure (RED-HF) trial [abstract].J Card Fail.12(suppl 1): S77.
67.
MixT.C.H., BrennerR.M., CooperM.E.Rationale-Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.Am Heart J.2005; 149: 408–413.
68.
Beck Da SilvaL., RohdeL.E., Perreira BarretoA.C.Rationale and Design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.J Cardiac Fail.2007; 13: 14–17.
69.
AthyrosV.G., KaragiannisA., KakafikaA., ElisafM., MikhailidisD.P.Statins and renal function. Is the compound and dose making a difference?Nephrol Dial Transplant.2007; 22: 963–964.
70.
ShepherdJ., KasteleinJ.J., BittnerV.; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.Clin J Am Soc Nephrol.2007; 2: 1131–1139.
71.
AthyrosV.G., MikhailidisD.P., PapageorgiouA.A.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study.J Clin Pathol.2004; 57: 728–734.
72.
AthyrosV.G., KaragiannisA., LiberopoulosE.N., ElisafM., MikhailidisD.P.Statin treatment may be beneficial to both the kidneys and the heart.Perit Dial Int.2007; 27: 215–216.
73.
CollinsR., ArmitageJ., ParishS., SleighP., PetoR.Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Lancet.2003; 361: 2005–2016.
74.
LiberopoulosE.N., MikhailidisD.P., AthyrosV.G., ElisafM.S.The effect of cholesterol-lowering treatment on renal function.Am J Kidney Dis.2006; 47: 561.
75.
DaskalopoulouS.S., AthyrosV.G., ElisafM., MikhailidisD.P.Uric acid levels and vascular disease.Curr Med Res Opin.2004; 20: 951–954.
76.
AthyrosV.G., MikhailidisD.P., LiberopoulosE.N.Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study.Nephrol Dial Transplant.2007; 22: 118–127.
77.
AthyrosV.G., ElisafM., PapageorgiouA.A.The effect of statins versus untreated dyslipidaemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study.Am J Kidney Dis.2004; 43: 589–599.
AthyrosV.G., KakafikaA., KaragiannisA., MikhailidisD.P.Statins and regression of coronary atherosclerosis.JAMA.2007; 297: 2197.
80.
KhushK.K., WatersD.D., BittnerV.Effect of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the Treating to New Targets (TNT) study.Circulation.2007; 115: 576–583.
81.
AthyrosV.G., KakafikaA.I., TziomalosK., KaragiannisA., MikhailidisD.P.CORONA, statins and heart failure. Who lost the crown:1Angiology. In press.
82.
AthyrosV.G., MikhailidisD.P., PapageorgiouA.A.; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease.J Hum Hypertens.2004; 18: 781–788.
83.
KontopoulosA.G., AthyrosV.G., PehlivanidisA.N., DemitriadisD.S., PapageorgiouA.A., BoudoulasH.Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.Curr Med Res Opin.2003; 19: 22–27.
84.
PehlivanidisA.N., AthyrosV.G., DemitriadisD.S., PapageorgiouA.A., BouloukosV.J., KontopoulosA.G.Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.Atherosclerosis.2001; 157: 463–469.
